VOR Vor Biopharma

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.

Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1

Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the Company’s website at:

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .

Media & Investor Contacts:

Carl Mauch

Sarah Spencer



EN
12/09/2025

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Office...

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer Dr. Khan brings decades of global medical affairs, commercial, and scientific leadership across multiple therapeutic areas including seven successful product launches CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs...

7h / 39m 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generaliz...

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscula...

September 17, 2025 1 EN
Wedbush Research
  • Wedbush Research
KMX CARMAX INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
VOR VOR BIOPHARMA
DNTH DIANTHUS THERAPEUTICS INC
NATL NCR ATLEOS CORPORATION
RNAC CARTESIAN THERAPEUTICS INC
09/16/25 September 16, 2025 1 EN
David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Martin Fan
ARGX ARGENX ADS
VOR VOR BIOPHARMA
DNTH DIANTHUS THERAPEUTICS INC
RNAC CARTESIAN THERAPEUTICS INC
09/16/25 September 16, 2025 1 EN
 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Infla...

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1Location: Virtual A live webcast and archived replay of the fireside chat will be available on the Company’s we...

September 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch